Curated news and analysis on clinical trials, drug approvals, and medical research.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
A Florida recidivist with a prior federal drug conviction and a Pennsylvania woman pleaded guilty to separate drug trafficking charges involving crack cocaine, methamphetamine, and synthetic cannabinoids. The Florida defendant faces at least 10 years to life, with sentencing set for September 3, 2026.
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
A Cochrane review found intermittent fasting did not beat standard diet advice for weight loss. A separate trial found it matched calorie restriction but felt less restrictive. Experts advise a case-by-case approach given limited evidence.
Tavapadon hit Phase 3 goals in early Parkinson's, FDA cleared GT-02287's trial, and risvodetinib reduced disease biomarkers in Phase 2. GEN dosed the first SUL-238 patient, and MJFF awarded $2.74M for XTS001 preclinical work.
TMates Weightloss Semaglutide is a compounded semaglutide telehealth program dispensed by U.S. pharmacies. It offers tailored dosing, a 30-day money-back guarantee, and support for appetite control and weight maintenance.
A divided appeals court ruled President Trump must halt construction of his 90,000-square-foot White House ballroom without congressional approval. The ruling followed an arts commission's fast-tracked approval of the $400 million project, which remains under legal challenge.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Adding bacteriostatic water to a 3mg semaglutide vial changes its concentration; the correct amount depends on the pharmacy's specification. FDA-approved semaglutide pens should not be reconstituted. The FDA has received reports of hospitalizations linked to compounded semaglutide dosing errors.
Adia Med has submitted an IRB study of AdiaVita for lower back pain and launched a redesigned website. The placebo-controlled crossover trial will enroll about 100 participants; an ASD study is also recruiting.
A WashU Medicine study found Moderna's investigational mRNA flu vaccine could reduce hospitalizations and deaths, offering longer protection than current shots. If FDA-approved, it would be the first mRNA flu vaccine, with a decision possible by early August.
TAVR panel at CRT 2026 explored the technology's current state and future. CathSAP's latest update includes new guidelines and trials, including EARLY TAVR and FDA approval for asymptomatic severe aortic stenosis.
Norton Rose Fulbright expands its pharma and biotech disputes team with February 2026 partner hires. A November 9, 2026 panel will examine shifting patent litigation, including Orange Book, Hatch-Waxman, and BPCIA disputes.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
